Influence of drugs on vitamin D and calcium metabolism

Dermato-Endocrinology

Volumn 4, Issue 2, 2012, Pages 158-166

  Gröber, Uwe ^a   Kisters, Klaus ^b  

^a Academy of Micronutrient Medicine   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

1,25 dihydroxyvitamin D 1,25(OH) 2D ; 25 hydroxy vitamin D 25(OH)D ; Bisphosphonates; Cytostatics; Drugs; Pregnane X receptor; Statins; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTIESTROGEN; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; COLECALCIFEROL; COLONY STIMULATING FACTOR 1; CYTOSTATIC AGENT; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM; PARATHYROID HORMONE; PREGNANE X RECEPTOR; TUBERCULOSTATIC AGENT; VITAMIN D; VITAMIN D RECEPTOR; XENOBIOTIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ASTHMA; BONE DENSITY; BONE DEVELOPMENT; BONE INJURY; BONE MASS; BONE METABOLISM; BONE METASTASIS; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; HORMONE SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPARATHYROIDISM; HYPERTENSION; INTESTINE ABSORPTION; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYALGIA; MYOSITIS; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOPOROSIS; PAGET BONE DISEASE; PROTEIN EXPRESSION; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; XENOBIOTIC METABOLISM;

EID: 84865194382     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.20731     Document Type: Review

References (68)

1. McCollum EF, Simmonds N, Becker JE, Shipley PG. Studies on experimental rickets and experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922; 53:293-312; PMID:11991957
2. Wolf G. The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr 2004; 134:1299-302; PMID: 15173387
3. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81; PMID:17634462; http://dx.doi.org/10.1056/NEJMra070553
4. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87(suppl):1080S-6S; PMID:18400738
5. Bartl R, Bartl C, Gradinger R. [Drug-induced osteopathies. Drugs, pathogenesis, forms, diagnosis, prevention and therapy]. Z Rheumatol 2010; 69:135-50, quiz 151; PMID:20146045
6. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115:177-86; PMID:15630458
7. Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J Clin Invest 2005; 115:32-4; PMID:15630441
8. Gröber U, Holick MF, Kisters K. [Vitamin D and drugs]. Med Monatsschr Pharm 2011; 34:377-87; PMID:22010421
9. Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is $33 ng/ml. [Epub ahead of print]. Osteoporos Int 2012; PMID:22237813; http://dx.doi.org/10.1007/s00198- 011-1868-7
10. Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas Laita A. Vitamin D levels and lipid response to atorvastatin. Int J Endocrinol, 2010; 2010:320721.
11. Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377:242-50; PMID: 21215445; http://dx.doi.org/10.1016/S0140-6736(10)61889-2
12. Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9:1695-709; PMID: 19018724; http://dx.doi.org/10.2217/14622416.9.11.1695
13. Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 1970; 4:69-72; PMID:5312062; http://dx.doi.org/10.1136/bmj.4.5727.69
14. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007; 18:129-42; PMID:17091219; http://dx.doi.org/10.1007/ s00198-006-0185-z
15. Valsamis HA, Arora SK, Labban B, McFarlane SI. Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) 2006; 3:36; PMID:16956398; http://dx.doi.org/10.1186/1743-7075-3-36
16. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45:1330-7; PMID:15509233; http://dx.doi.org/10.1111/j.0013-9580.2004.18804.x
17. Gröber U, Arzneimittel und Mikronährstoffe. Medikationsorientierte Supplementierung. 2. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2012.
18. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ, III, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893-9; PMID:15125788; http://dx.doi.org/10.1359/JBMR.040134
19. Dachverband Osteologie e.V. (DVO). Prophylaxe, Diagnostik und Therapie der Glukokortikoid-induzierten Osteoporose (2006) bei Erwachsenen (2006)
20. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993-1000; PMID:10841167; http://dx.doi.org/10.1359/jbmr.2000.15.6.993
21. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48:3224-9; PMID:14613287; http://dx.doi.org/10.1002/art.11283
22. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000; 9:359-66; PMID:19025840; http://dx.doi.org/10. 1002/1099-1557 (200009/10)9:5〈359::AID-PDS507〉3.0.CO;2-E
23. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59 (Suppl 1):48-52; PMID:10769437; http://dx.doi.org/10.1007/s003930070040
24. Allen AC, Kelly S, Basdeo SA, Kinsella K, Mulready KJ, Mills KH, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. [Epub ahead of print]. Mult Scler 2012; PMID:22457344; http://dx.doi.org/10.1177/1352458512442992
25. Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. [Epub ahead of print]. J Neurol Neurosurg Psychiatry 2012; 83:565-71; PMID:22362918; http://dx.doi.org/10.1136/jnnp-2011-301876
26. Ginde AA, Mansbach JM, Camargo CA, Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169:384-90; PMID:19237723; http://dx.doi.org/10.1001/archinternmed.2008.560
27. Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al. Childhood Asthma Management Program Research Group. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010; 126:52-8, e5; PMID: 20538327; http://dx.doi.org/10.1016/j.jaci.2010.03.043
28. Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DY. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010; 125:995-1000; PMID:20381849; http://dx.doi.org/10.1016/j.jaci.2010.03.008
29. Bozzetto S, Carraro S, Giordano G, Boner A, Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy 2012; 67:10-7; PMID:21933195; http://dx.doi.org/10.1111/j.1398-9995.2011.02711.x
30. Berruti A, et al. Effect of zoledronic acid (z) treatment based on serum parathyroid hormone (pth) levels in patients (pts) with malignant bone disease. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement): abstract 8610.
31. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006; 17:1336-7; PMID:16524968; http://dx.doi.org/10.1093/annonc/mdl045
32. Deane A, Constancio L, Fogelman I, Hampson G. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in postmenopausal osteoporosis. BMC Musculoskelet Disord 2007; 8:3; PMID:17214897; http://dx.doi.org/10.1186/1471-2474-8-3
33. Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20:239-44; PMID:18551242; http://dx.doi.org/10.1007/s00198- 008-0650-y
34. Bruyère O, Reginster JY. Vitamin D status and response to antiosteoporotic therapy. [London Engl]. Womens Health (Lond Engl) 2008; 4:445-7; PMID: 19072484; http://dx.doi.org/10.2217/17455057.4.5.445
35. Ginde AA, Wolfe P, Camargo CA, Jr., Schwartz RS. Defining vitamin D status by secondary hyperparathyroidism in the U.S. population. J Endocrinol Invest 2012; 35:42-8; PMID:21606669
36. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-74; PMID:17086056; http://dx.doi.org/10.1097/QAD.0b013e32801022eb
37. Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010; 54:123-32; PMID:20485900; http://dx.doi.org/10.1590/ S0004-27302010000200007
38. Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther 2011; 16:1063-72; PMID:22024522; http://dx.doi.org/10.3851/IMP1874
39. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-8; PMID:20588161; http://dx.doi.org/10.1097/QAD. 0b013e32833c3281
40. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1375-82; PMID:18928396; http://dx.doi.org/10.1089/aid.2008.0058
41. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-42; PMID: 12802030; http://dx.doi.org/10.1056/NEJMra023246
42. Servitja S, Nogués X, Prieto-Alhambra D, Martínez- García M, Garrigós L, Peña MJ, et al. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast 2012; 21:95-101; PMID:21924904; http://dx.doi.org/ 10.1016/j.breast.2011.09.001
43. Khan QJ, O'Dea AP, Sharma P, Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol, 2010; 2010. pii: 654348.
44. Aktories K, Förstermann U, Hofmann FB, Starke K, eds. Allgemeine und spezielle Pharmakologie und Toxikologie. 10. Auflage. München: Elsevier, Urban & Fischer, 2009.
45. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48:417-28; PMID:2879636; http://dx.doi.org/10.1016/0092-8674(87)90193-0
46. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78-84; PMID:8558225
47. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, non-specific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463-70; PMID:14661675; http://dx.doi.org/10.4065/78.12.1463
48. Lønning PE. Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 2006; 16(Suppl 2):518-20; PMID:17010062; http://dx.doi.org/10.1111/j.1525-1438.2006.00685.x
49. Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int 1986; 39:139-44; PMID: 3093024; http://dx.doi.org/10.1007/ BF02555109
50. Cheema C, Grant BF, Marcus R. Effects of estrogen on circulating "free" and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest 1989; 83:537-42; PMID: 2492309; http://dx.doi.org/10.1172/JCI113915
51. Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol 2005; 185:577-92; PMID:15930183; http://dx.doi.org/10.1677/joe.1.05770
52. Escaleira MT, Sonohara S, Brentani MM. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol 1993; 45:257-63; PMID:8388708; http://dx.doi.org/10.1016/0960- 0760(93)90340-3
53. Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez- García M, Diez-Perez A, et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 2011; 125:869-78; PMID:20665105; http://dx.doi.org/10.1007/s10549-010- 1075-9
54. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119: 111-8; PMID:19655244; http://dx.doi.org/10. 1007/s10549-009-0495-x
55. Khan QJ, Kimler BF, Fabian CJ. The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep 2010; 12:136-42; PMID:20425599; http://dx.doi.org/10.1007/s11912-010-0081-8
56. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007; 99:1594-602; PMID:17971526; http://dx.doi.org/10.1093/jnci/djm204
57. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27:3757-63; PMID:19451439; http://dx.doi.org/10.1200/JCO.2008.20.0725
58. Santini D, Galluzzo S, Vincenzi B, Zoccoli A, Ferraro E, Lippi C, et al. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21:185-6; PMID: 19892747; http://dx.doi.org/10.1093/annonc/mdp497
59. Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29:e81-2; PMID: 21060025; http://dx.doi.org/10.1200/JCO.2010.31.5317
60. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens 2009; 27:1948-54; PMID:19587609; http://dx.doi.org/10.1097/HJH.0b013e32832f075b
61. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-38; PMID:12122115
62. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88:327-31; PMID: 12520534; http://dx.doi.org/10.1002/jcb.10343
63. Gupta AK, Sexton RC, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res 1989; 30:379-86; PMID:2542424
64. Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas Laita A. Vitamin d levels and lipid response to atorvastatin. Int J Endocrinol 2010; 2010:320721; PMID:20016682; http://dx.doi.org/10.1155/2010/320721
65. Glueck CJ, Budhani SB, Masineni SS, Abuchaibe C, Khan N, Wang P, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011; 27:1683-90; PMID: 21728907; http://dx.doi.org/10.1185/ 03007995.2011.598144
66. Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153:11-6; PMID:19100953; http://dx.doi.org/10.1016/j.trsl.2008.11.002
67. Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 2009; 7:e001; PMID: 19240808
68. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006; 116:1703-12; PMID:16691293; http://dx.doi.org/10.1172/JCI27793